David Spetzler, Ph.D., MBA, serves as President of Caris Life Sciences, a leading precision medicine company revolutionizing cancer care through molecular profiling and AI-driven insights. With over two decades of experience in biotechnology and diagnostics, Spetzler joined Caris in 2012 as Chief Scientific Officer, where he spearheaded the development of the company's flagship Molecular Intelligence platform. Prior to Caris, he held senior roles at Ventana Medical Systems (a Roche company), leading companion diagnostic programs and advancing personalized medicine technologies. His earlier career included positions at ASU Biodesign Institute and Array BioPharma, focusing on bioinformatics and drug discovery. Under Spetzler's leadership, Caris has profiled over 500,000 patient tumors, establishing the world's largest molecular oncology database and enabling breakthroughs in immunotherapy and targeted therapies. He has driven innovations such as the Caris AI platform, which integrates whole exome and transcriptome sequencing with machine learning to deliver actionable intelligence for oncologists. Spetzler's strategic vision has positioned Caris as a pioneer in real-world evidence generation, with numerous peer-reviewed publications, patents, and collaborations with pharmaceutical leaders. As President, Spetzler oversees global operations, commercial strategy, and R&D, ensuring Caris remains at the forefront of precision oncology. His expertise in AI, big data, and clinical translation has earned him recognition as a thought leader, including speaking engagements at major conferences like ASCO and AACR. Spetzler's commitment to improving patient outcomes continues to propel Caris' mission of transforming cancer into a manageable disease.